Osteoporosis testing and treatment remain low in both Traditional Medicare and Medicare Advantage
Main finding · BMD testingResult — go to the resultAdjusted difference 0.8 percentage pointsAuthors' conclusion
Overall osteoporosis testing and treatment initiation rates in both TM and MA enrollees were low, with improved rates in MA compared to TM.
Study context
- Population
- Female Medicare beneficiaries in the United States, 2017–2019
- Participants
- 1,924,132 vs 2,994,203
- Exposure
- Medicare Advantage vs Traditional Medicare
- Medicare Advantage (MA)n = 1,924,132
- Traditional Medicare (TM)n = 2,994,203reference
- Outcome
- Rates of guideline-recommended bone mineral density (BMD) testing and osteoporosis drug initiation following a new osteoporosis diagnosis and after a new osteoporotic fragility fracture
Methodological detailsnationally representative 20% sample of 2017-2019 TM claims and MA encounter records
- Nationally representative 20% sample of 2017-2019 TM claims and MA encounter records
Main finding
BMD testing
Adjusted difference
0.8 percentage points
P < 0.001
By group
As reported in the abstract
Observational data: associations, not effects.
Further findings
Primary: osteoporosis drug treatment initiation
P < 0.001
Primary: pharmacologic treatment prescribed after osteoporotic fragility fracture
P < 0.001
| Outcome | Estimate | P value |
|---|---|---|
| Primary: osteoporosis drug treatment initiation | adjusted difference 4.0 percentage points | P < 0.001 |
| Primary: pharmacologic treatment prescribed after osteoporotic fragility fracture | adjusted increase 5.9 p.p | P < 0.001 |
Original publication
Osteoporosis testing and treatment remain low in both Traditional Medicare and Medicare Advantage. Osteoporos Int. Published 21 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →